Palbociclib

哌柏西利

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NamePalbociclib
Drug Alias NamePalbocicilib帕博昔布Palbocilib帕博西尼Iburance +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerSolid tumours +[41] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2015/02/03
Country/TerritoryCzechiaBelgiumCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteCelcuity IncWashington University School Of Medicine +[11] 
Inactive CompaniesUniversity Of California San FranciscoWeill Medical College of Cornell UniversityBiotx ai GmbH +[11] 
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[14] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesRenal Insufficiency +[27] 

Other Information

ATC CodeL01EF01
Related LinksWikipediaDrugBankKEGG